Vicarious Surgical Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RBOT research report →
Range $7 – $10.5
Price Chart
About the company
Vicarious Surgical Inc. is dedicated to the development and commercialization of advanced single-incision surgical robotics. Their innovative technology is designed to give surgeons a virtual, immersive presence within the patient's body, facilitating highly precise and minimally invasive operations.
- CEO
- Stephen From
- IPO
- 2020
- Employees
- 48
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on RBOT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $453.42K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.13
- EV/EBITDA
- -0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -333.19%
- ROIC
- -396.87%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,425,000+32.4%
- Op Income
- $-50,968,000
- Net Income
- $-50,182,000+20.6%
- EPS
- $-8.45+21.2%
- OCF Growth
- +9.8%
- FCF Growth
- +9.8%
- 52W High
- $7.45
- 52W Low
- $0.02
- 50D MA
- $0.05
- 200D MA
- $0.85
- Beta
- 1.86
- RSI (14)
- 53
- Avg Volume
- 48.13K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Vicarious Surgical reported a narrower Q3 loss and lower spending, while centering the call on design freeze by year-end 2026 and aggressive burn reduction through outsourcing and layoffs.· November 12, 2025
- Q3 operating expenses fell 35% year over year to $11.5 million, driving a narrower GAAP net loss of $11.1 million, or $1.86 per share.
- Management reiterated its target to complete design freeze of the production-equivalent system by year-end 2026.
- The company is pursuing outsourcing for less-differentiated components, with PA Consulting expected to finish its gap analysis and recommendations by the end of November.
- Vicarious cut headcount by about 15% and is targeting materially lower burn in 2026 after raising additional capital in October and again after quarter-end.
- Management said surgeon testing has been frequent and that internal labs have shown better stability and faster suturing times, including a drop from about 40 minutes to 14 minutes in one procedure.
Total operating expenses were $11.5 million in Q3 2025, down 35% from $17.8 million in Q3 2024. R&D expense was $8 million versus $10.8 million a year ago; G&A was $3.2 million versus $5.7 million; and sales and marketing was $350,000 versus $1.2 million. GAAP net loss was $11.1 million, or $1.86 per share, compared with a GAAP net loss of $17.1 million, or $2.90 per share, in Q3 2024. Non-GAAP adjusted net loss was $11.3 million, or $1.91 per share, versus $17 million, or $2.87 per share, last year. The company ended Q3 with about $13.4 million of cash, cash equivalents and short-term investments, and cited a third-quarter cash burn rate of about $10.5 million. Following quarter-end, it completed a registered direct offering with about $5.2 million in net proceeds, and management continues to expect full-year 2025 cash burn of approximately $50 million.
Stephen From said he has shifted the company from assessment to execution, with a clear focus on reaching design freeze, extending runway through burn reduction, and improving communication. He emphasized that the core technology areas to protect are the robotic arms, camera systems and core software, while outsourcing less unique capital equipment work. His tone was candid and operational, repeatedly acknowledging that some disruption is likely but saying the company will try to communicate issues more quickly and directly.
Sarah Romano highlighted the year-over-year expense reduction across the cost structure, including the 35% drop in total operating expenses to $11.5 million. She noted Q3 cash burn of about $10.5 million, cash and investments of about $13.4 million at quarter-end, and the additional $5.2 million in net proceeds from the post-quarter registered direct offering. She reiterated full-year 2025 cash burn guidance of approximately $50 million and said the company is actively focused on reducing burn in 2026 and exploring further ways to bolster the balance sheet.
Analysts focused on whether outsourcing would delay the build timeline and whether the company was effectively restarting work on the system. Management said it is still targeting design freeze toward the end of 2026, expects some disruption but hopes it will not materially affect timing, and stressed that the work is an upgrade of an evolving build rather than a restart. They also said PA Consulting was brought in for a short, fixed-fee engagement to pressure-test the outsourcing plan, with an aim to have much of the structure in place by the end of Q1.
Management described visible progress in surgeon testing, saying the company has been running OR labs almost weekly and has seen improved stability and reliability in the system. Stephen From cited a dramatic reduction in suturing time from about 40 minutes to 14 minutes in an IPOM ventral hernia workflow, and said hospital and health-system relationships remain strong. The company also has taken concrete steps to reduce burn, including layoffs, outsourcing review, and additional capital raising.
The company is still early in outsourcing, and management acknowledged that the effort may create disruption and could affect timing. The plan to reach design freeze by year-end 2026 remains a target rather than a certainty, and the company still needs to complete the consulting work, RFPs and vendor decisions. Cash remains limited at $13.4 million at quarter-end, and management said it is actively exploring further balance-sheet support while expecting about $50 million of full-year 2025 burn.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 64.2%
- Shares Outstanding
- 6.48M
- Float Shares
- 4.16M
of shares held by institutions
36 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 141.25K | ▼ 2.03K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 20, 26 | Sachs Adam David | sell | 942 |
| Feb 20, 26 | Khalifa Sammy | sell | 754 |
| Dec 3, 25 | Sachs Adam David | sell | 463 |
| Dec 3, 25 | Khalifa Sammy | sell | 239 |
| Nov 20, 25 | Khalifa Sammy | sell | 653 |
| Nov 20, 25 | Sachs Adam David | sell | 816 |
| Jun 27, 25 | Doherty Joseph Edward | other | 8,003 |
| Jun 27, 25 | Doherty Joseph Edward | other | 0 |
| Sep 3, 25 | Sachs Adam David | sell | 463 |
| Sep 3, 25 | Khalifa Sammy | sell | 239 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RBOT coverage
Recent articles, reports, and earnings notes.
No research on RBOT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RBOT report →Vicarious Surgical Demonstrates Sustained System Performance and Complex Hernia Procedure Workflows in Pre-Clinical Setting
globenewswire.com · May 13
Vicarious Surgical Reports First Quarter 2026 Financial Results
globenewswire.com · Apr 30
Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
globenewswire.com · Mar 30
Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
globenewswire.com · Mar 25
Head-To-Head Survey: Waters (NYSE:WAT) vs. Vicarious Surgical (NYSE:RBOT)
defenseworld.net · Mar 19
Vicarious Surgical Announces Strategic Plan to Pursue Nasdaq Listing
businesswire.com · Mar 16
Vicarious Surgical Reports Fourth Quarter and Full Year 2025 Financial Results
businesswire.com · Mar 9
Vicarious Surgical Receives Delisting Notice From NYSE
businesswire.com · Mar 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.